Why the study?
Changing patient characteristics and pathophysiology in acute heart failure have shifted the therapeutic focus from early symptom relief toward therapies targeting neurohormonal and inflammatory dysregulation for long-term remission.
This review emphasizes a paradigm shift in acute heart failure management from short-term symptom relief to achieving remission through rapid initiation of guideline-directed medical therapy and potential anti-inflammatory treatments.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for remission via rapid GDMT in acute HF; prospective RCTs required before practice change.
During the past century, the characteristics of patients with heart failure (HF) and acute HF (AHF) have shifted from patients with severe pump failure due to rheumatic, hypertensive and ischemic heart disease to older and more obese patients with multiple severe comorbidities. The pathophysiology of AHF has shifted, in parallel, from that of advanced, end-stage pump failure caused by severe left ventricular dysfunction to age, obesity and comorbidity-related cardiovascular dysfunction combined with neurohormonal and inflammatory dysregulation or "inflammaging." With the advent of neurohormonal blockers leading to improved outcomes of patients with chronic HF, the focus of AHF therapy has also changed from care directed at early symptom improvement to therapies directed toward longer-term improvements in quality of life and outcomes. Studies conducted in the past 5 years suggest that the beneficial effects seen with the 4 pillars of guideline-directed medical therapy for HF, mostly comprising neurohormonal blockade, can be extended to AHF when these therapies are initiated and rapidly uptitrated during admission and after discharge. A recent pilot study, CORTAHF (Effect of Short-Term Prednisone Therapy on CRP Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers), has suggested that these benefits can be extended by treating patients with AHF and markers of inflammatory activation with anti-inflammatory therapies. Future studies should further examine whether combined anti-inflammatory therapy and neurohormonal blockade can lead to the reversal of disrupted underlying pathophysiology and remission in patients with AHF.
No takes yet. Share an insight, caveat, or question.
Cotter et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: